Prevalence, Clinical and Virologic Outcomes of Hepatitis B Virus Co-Infection in HIV-1 Positive Kenyan Women on Antiretroviral Therapy

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Day, Summer L ^a   Odem Davis, Katherine ^a,b   Mandaliya, Kishorchandra N ^c   Jerome, Keith R ^a,b   Cook, Linda ^a,b   Masese, Linnet N ^a   Scott, John ^a   Kim, H Nina ^a   Graham, Susan M ^a,d   McClelland, R Scott ^a,d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b USA   (United States)

^c Pathcare Laboratories   (Kenya)

^d UNIVERSITY OF NAIROBI   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; NEVIRAPINE; STAVUDINE; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; KENYA; LONG TERM CARE; MAJOR CLINICAL STUDY; MIXED INFECTION; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDY; SEROPREVALENCE; VIRUS INHIBITION; VIRUS LOAD;

ADULT; ALANINE TRANSAMINASE; ANTI-RETROVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; COINFECTION; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; HEPATITIS B; HIV INFECTIONS; HIV-1; HUMANS; KAPLAN-MEIER ESTIMATE; KENYA; LAMIVUDINE; LOGISTIC MODELS; PREVALENCE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SEX WORKERS; TREATMENT OUTCOME;

EID: 84875075906     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059346     Document Type: Article

References (39)

1. Modi AA, Feld JJ, (2007) Viral hepatitis and HIV in Africa. AIDS Rev 9: 25-39.
2. Hoffmann CJ, Thio CL, (2007) Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis 7: 402-409.
3. Levanchy D, (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11: 97-107.
4. Soriano V, Puoti M, Peters M, Benhamou Y, Sulkowski M, et al. (2008) Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 22: 1399-1410.
5. Puoti M, Torti C, Bruno R, Filice G, Carosi G, (2006) Natural history of chronic hepatitis B in co-infected patients. J Hepatol 44: S65-S70.
6. Hoffmann CJ, Charalabous S, Desmond MJ, Innes C, Churchyard GJ, et al. (2008) Hepatitis B Virus infection and response to Antiretroviral Therapy (ART) in a South African ART Program. Clin Infect Dis 47: 1479-1485.
7. Barth RE, Huijgen Q, Taljaard J, Hoepelman AI, (2010) Hepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis. Int J Infect Dis 14: e1024-e1031.
8. Ford N, Calmy A, (2010) Improving first-line antiretroviral therapy in resource-limited settings. Curr Opin HIV AIDS 5: 38-47.
9. Benhamou Y, Bochet M, Thibault V, Martino VD, Caumes E, et al. (1999) Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 30: 1302-1306.
10. UNAIDS (2010) Global Report: UNAIDS report on the global AIDS epidemic. Geneva: Available: http://www.unaids.org/globalreport/global_report.htm Accessed 2012 Sep 10: 1-364.
11. World Health Organization (WHO) (2010 Revision) Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. Available: http://www.who.int/hiv/pub/guidelines/adult/en/index.html. Accessed 2012 May 10.
12. Kouanfack C, Aghokeng AF, Mondain AM, Bourgeois A, Kenfack A, et al. (2012) Lamivudine-resistant HBV infection in HIV-positive patients receiving antiretroviral therapy in a public routine clinic in Cameroon. Antivir Ther 17: 321-326.
13. Matthews GV, Manzini P, Hu Z, Khabo P, Maja P, et al. (2011) Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa. AIDS 25: 1727-1735.
14. Geretti AM, Patel M, Sarfo FS, Chadwick D, Verheyen J, et al. (2010) Detection of highly prevalent hepatitis B virus coinfection among HIV-seropositive persons in Ghana. J Clin Microbiol 48: 3223-3229.
15. Stewart B, Jobarteh J, Sarge-Njie R, Alabi A, Peterson K, et al. (2011) Emergence of HBV resistance to lamivudine (3TC) in HIV/HBV co-infected patients in The Gambia, West Africa. BMC Res Notes 4: 561.
16. Kim NH, Scott J, Cent A, Cook L, Morrow RA, et al. (2011) HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine, and nevirapine in Kenya. J Viral Hepat 18: e447-452.
17. Graham SM, Masese L, Gitau R, Jalalian-Lechak Z, Richardson BA, et al. (2010) Antiretroviral adherence and development of drug resistance are the strongest predictors of genital HIV-1 shedding among women initiating treatment. J Infect Dis 202: 1538-1542.
18. McClelland RS, Hassan W, Lavreys L, Richardson BA, Mandaliya K, et al. (2006) HIV-1 acquisition and disease progression are associated with decreased high-risk sexual behaviour among Kenyan female sex workers. AIDS 20: 1969-1973.
19. Law W, Dore G, Duncombe C, Mahanontharit A, Boyd MA, et al. (2003) Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS 17: 2191-2199.
20. Matthews GV, Bartholomeusz A, Locarnini S, Ayres A, Sasaduesz J, et al. (2006) Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 20: 863-870.
21. Ramos B, Nunez M, Martin-Carbonero L, Sheldon J, Rios P, et al. (2007) Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients. J Acquir Immune Defic Syndr 44: 557-561.
22. Kramvis A, Kew M, (2005) Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy. J Viral Hepat 12: 456-464.
23. Liu C, Kao J, Chen D, (2005) Therapeutic Implications of hepatitis b virus genotypes. Liver International 25: 1097-1107.
24. Zollner B, Schafer P, Feucht H, Schroter M, Petersen J, et al. (2001) Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy. J Med Virol 65: 659-663.
25. Zollner B, Petersen J, Schafer P, Schroter M, Laufs R, et al. (2002) Subtype-dependent response of hepatitis B virus during the early phase of lamivudine treatment. Clin Infect Dis 34: 1273-1277.
26. Buti M, Cotrina M, Valdes A, Jardi R, Rodriguez-Frias F, et al. (2002) Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine?. J Hepatol 36: 445-446.
27. Suzuki F, Tsubota A, Arase Y, Suzuki Y, Akuta N, et al. (2003) Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan. Intervirology 46: 182-189.
28. Kao J, Liu C, Chen D, (2002) Hepatitis B viral genotypes and lamivudine resistance. J Hepatol 36: 303-304.
29. Akuta N, Suzuki F, Kobayashi M, Tsubota A, Suzuki Y, et al. (2003) The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. J Hepatol 38: 315-321.
30. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, LI C,et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. The New England Journal of Medicine 342: 921-929.
31. Moskovitz D, Osiowy C, Giles E, Tomlinson G, Heathcote E, (2005) Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance. J Viral Hepat 12: 398-404.
32. Li X, Wang L, Liu Y, Xu Z, Dai J, et al. (2011) Characterization of hepatitis B virus genotypes/subgenotypes in 1,301 patients with chronic hepatitis B in North China. Chin Med J 124: 4178-4183.
33. Wu F, Wu M, Zhuge X, Zhu S, Zhu B, (2012) Correlation of the occurrence of YMDD mutations with HBV genotypes, HBV-DNA levels, and HBeAg status in Chinese patients with chronic hepatitis B during lamivudine treatment. Hepatobiliary Pancreat Dis Int 11: 172-176.
34. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, et al. (2003) Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis. 36: 687-696.
35. Wongprasit P, Manosuthi W, Kiertiburanakul S, Sungkanuparph S, (2010) Hepatitis B virus drug resistance in HIV-1-infected patients taking lamivudine-containing antiretroviral therapy. AIDS Pat Care STDS 24: 205-209.
36. Moerman B, Moons V, Sommer H, Schmitt Y, Stetter M, (2004) Evaluation of sensitivity for wild type and mutant forms of hepatitis B surface antigen by four commercial HBsAg assays. Clin Lab 50: 159-162.
37. La'ulu S, Roberts W, (2006) The analytic sensitivity and mutant detection capability of six hepatitis B surface antigen assays. Am J Clin Pathol 125: 748-751.
38. Ma Q, Wang Y, (2012) Comprehensive analysis of the prevalence of hepatitis B virus escape mutations in the major hydrophilic region of surface antigen. J Med Virol 84: 198-206.
39. Shaikh T, Cooper C, (2012) Reassessing the role of lamivudine in chronic hepatitis B infection: a four-year cohort analysis. Can J Gastroenterol 26: 148-150.